(Reuters) - Biogen Idec Inc is pricing its newly-approved long-acting hemophilia drug to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.
via Reuters: Health News Read More Here..
No comments:
Post a Comment